Through the new DTP platform, Novartis will make Cosentyx available to patients at a price that reflects the average savings typically retained by insurers and pharmacy benefit managers
The acquisition positions ACL Digital as an end-to-end provider of global clinical research and data CRO solutions
BPDCN is a challenging blood cancer with characteristics of both leukemia and lymphoma
Miels will formally assume the role on January 1, 2026
The Hub & Spoke model is designed to extend advanced medical care to a wider community
Brenntag will showcase forward-looking formulations designed to respond to Indonesia’s evolving beauty and self-care needs
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Subscribe To Our Newsletter & Stay Updated
